Oxford Global Conferences Ltd are proud to present the 3rd Annual Biosimilars & Biobetters Congress, taking place on 20 – 21 April 2015 in London, UK at the Novotel London West. The congress is an exclusive opportunity for over 350 biologics experts to exchange their experiences, engage in scientific discussions and debate the best practices and solutions to improve the biosimilars industry performance.
Despite having to overcome tight regulatory, business and financial challenges, the biosimilars industry is forecast to be worth up to $25 billion by 2020. The rapid growth of the industry requires biosimilar experts to be at the forefront of knowledge with the current landscape of the industry.
The 3rd Annual Biosimilars & Biobetters Congress forms part of Oxford Global’s highly successful Biologics Series. For more information on other events in this series, please see the details below:
In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with our advisory board members including VPs, Directors, Senior Research Fellows and Professors from global pharmaceutical organisations and leading research institutions.
Day 1 – Market Access Strategies, Opportunities And Commercial Challenges
Day One will explore biosimilars market access strategies, opportunities and commercial challenges. Our esteemed speakers will provide the latest regulatory updates and multiple perspectives on biosimilars. Presentations will also provide an insight into market access initiatives and opportunities in emerging markets, case studies on global commercialisation strategies and evaluating the current market for biosimilars success.
- Assessing the landscape of biosimilars: interchangeability and substitution
- Evaluating the current market for biosimilar success: challenges, opportunities and barriers
- Case studies on global commercialisation strategies
- Market access initiatives and opportunities in emerging markets
- Regulatory updates on biosimilars
- Balancing technological innovation with regulatory requirements
Day 2 – Developing Biosimilars And Biobetters
Day Two will focus on biosimilars and biobetters development. Internationally renowned speakers will discuss current challenges and obstacles in the development of biosimilars and the latest solutions to demonstrate biosimilarity. Delegates will also have the opportunity to hear different characterisation methods, industry case studies on biosimilar mAb development and clinical and non-clinical advances in biosimilars.
- Demonstrating biosimilarity: challenges and solutions
- Clinical and non-clinical advances in biosimilars
- Characterisation methods: physio-chemical characterisation, structural characterisation, glycosylation analysis
- Future challenges and obstacles in biosimilar development
- Ensuring the quality of follow-on biologics: analytical testing, downstream processing
- Analytical development and formulation strategies for follow-on biologics
Who is Speaking
Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable knowledge share and facilitate idea exchange.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Eszter Nagy.
2015 Confirmed Speakers
Senior Director Regulatory Affairs, Baxter
Director, Lixisenatide Family Projects – Diabetes, Sanofi
Director – Alliance Management (Biosimilars), Merck Serono
Life Sciences Development Director, NHS
Chairman, Harvest Moon Pharmaceuticals USA, Inc.
Vice President R&D, Global Head, Biologics Safety Assessment, MedImmune
Business Unit Manager Oncology and Oco-Biotechnology, Egis Pharmaceuticals
Head of Safety, Biosimilars, Merck Serono
Oncology Portfolio Global Medical Lead – Biosimilars, Pfizer
Technical Development CMC Manager, Biosimilars, Biogen Idec
Takashi Kei Kishimoto
Chief Scientific Officer, Selecta Biosciences
Senior Medical Director, Global Medical Affairs, Sanofi
Vice President of Business Development, Alvotech
Senior Director and Global Head of Bioassays, Teva
Global Commercial Manager, mABs, Cassara Biotech
Senior Medical Fellow, Clinical Pharmacology, Eli Lilly
Senior Manager, Emerging Markets Regulatory Policy, Pfizer
Director, Business Development, Merck Serono
Director – Business Intelligence, Sanofi
Director Purification and Formulation Science, Boehringer Ingelheim
Benita von Glahn
Head of Regulatory Affairs, Biosimilars, Boehringer Ingelheim
Submit a poster
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
How to submit your abstract
We will require:
- Poster title, Abstract (200 words or less)
- Principal author, Organisation, Mailing address
- Email, Telephone, Fax
- Additional authors
In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.
To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available so please register soon!
Who Will Attend
The 3rd Annual Biosimilars & Biobetters Congress is an exclusive event designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Delegates typically include VPs, Directors and Global Heads of:
- Biobetter Development
- Biologics Development
- Biosimilar Development
- Biosimilar Process Development
- Commercial Affairs and Development
- Follow-On Biologics
- Market Access
- Market Entry SBMP
- Portfolio Management
- Product Development
- Regulatory Compliance
- Regulatory/Legal Affairs
- Research & Development
- Strategic Marketing
- Strategic Planning